UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/555,894	11/07/2005	Jordi Tormo i Blasco	4266-0146PUS1	2720
2292 7590 11/17/2008 BIRCH STEWART KOLASCH & BIRCH PO BOX 747 FALLS CHARGEL VA 22040 0747			EXAMINER	
			JARRELL, NOBLE E	
FALLS CHURCH, VA 22040-0747			ART UNIT	PAPER NUMBER
			1624	
			NOTIFICATION DATE	DELIVERY MODE
			11/17/2008	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

mailroom@bskb.com

	Application No.	Applicant(s)		
	10/555,894	TORMO I BLASCO ET AL.		
Office Action Summary	Examiner	Art Unit		
	NOBLE JARRELL	1624		
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet with the	correspondence address		
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D - Extensions of time may be available under the provisions of 37 CFR 1.7 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATIO 136(a). In no event, however, may a reply be tin will apply and will expire SIX (6) MONTHS from e, cause the application to become ABANDONE	N. mely filed n the mailing date of this communication. ED (35 U.S.C. § 133).		
Status				
1) ☐ Responsive to communication(s) filed on <u>02 S</u> 2a) ☐ This action is FINAL . 2b) ☐ This 3) ☐ Since this application is in condition for allowated closed in accordance with the practice under the process of th	s action is non-final. ince except for formal matters, pr			
Disposition of Claims				
4) ☐ Claim(s) 1,2 and 5-16 is/are pending in the ap 4a) Of the above claim(s) 6-10 and 12 is/are w 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1,2 and 5 is/are rejected. 7) ☐ Claim(s) 11,13-16 is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or	ithdrawn from consideration.			
Application Papers				
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomposed and applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examine 11.	cepted or b) objected to by the drawing(s) be held in abeyance. Se tion is required if the drawing(s) is ob	ee 37 CFR 1.85(a). ojected to. See 37 CFR 1.121(d).		
Priority under 35 U.S.C. § 119				
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 				
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:	oate		

Application/Control Number: 10/555,894 Page 2

Art Unit: 1624

DETAILED ACTION

Response to Arguments

- 1. The rejection under 35 U.S.C. 103 has been overcome by the amendment filed 9/2/08.
- 2. The double patenting rejection under obviousness has been overcome by the amendment filed 9/2/08.

Claim Objections

3. Claims 14 and 16 are objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. There is no antecedent basis for variable R⁴ being a triazole ring in claim 1.

Claim Rejections - 35 USC § 103

- 4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 5. The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:
 - 1. Determining the scope and contents of the prior art.
 - 2. Ascertaining the differences between the prior art and the claims at issue.
 - 3. Resolving the level of ordinary skill in the pertinent art.
 - 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
- 6. Claims 1, 2, and 5 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ibrahim et al. (*Egyptian Journal of Pharmaceutical Sciences*, **1998**, *39(1-3)*, 185-195).

Determining the scope and contents of the prior art

Ibrahim et al. teach a compound 3 (page 186) in which variable R⁴ is a 4,5-dihydro-3-methyl-5-oxo-1*H*-pyrazol-1-yl ring, NR¹R² is NH₂, variable R³ is CN (nitrile or cyano), variable L is H, and subscript n is 5. This compound can be used in a variety of ways, including as an anticancer agent, an analgesic, or a bactericide (page 185).

Ascertaining the differences between the prior art and the claims at issue

In the structure reported by Ibrahim et al., variable R³ is attached to the 5-position of the pyrimidine ring and the phenyl ring with substituent L is connected is attached to the 4-position of the pyrimidine ring. In the instant application, variable R³ is attached to the 4-position of the pyrimidine ring and the phenyl ring with substituent L is connected is attached to the 5-position of the pyrimidine ring.

Resolving the level of ordinary skill in the pertinent art

One of ordinary skill in the art can control substitution on different points of attachment on a pyrimidine ring.

Considering objective evidence present in the application indicating obviousness or nonobviousness

In re Norris (84 USPQ 458) teaches that: "Novel and useful compound, which is isomeric with compounds of prior art is not patentable where new compound is not shown to possess new and unexpected properties."

In re Lohr and Spurlin (137 USPQ 54) teaches that H v. Me is not considered patentable evidence of superior, unexpected results. In this case, an H substituent is considered an analogue of a methyl group because the two groups only differ by CH₂.

In the instant case, it would be obvious to try the specified prepared by Ibrahim et al. because it is a positional isomer of the formula I of the current set of claims and H v. Me is not considered

Application/Control Number: 10/555,894 Page 4

Art Unit: 1624

patentable for a compound with this core structure. Applicants must show that the positioning of the phenyl ring and variable R³ is critical to the invention in order to overcome the rejection and/or that H v. Me does produce a critical difference in activity of the compound.

Conclusion

- 7. Claims 11, 13, and 15 appear free of the prior art of record.
- 8. Claims 11, 13 and 15 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
- 9. The following is a statement of reasons for the indication of allowable subject matter: Ibrahim et al. (same reference as 103(a)) teach the closest prior art of record. In this compound, variable R⁴ is a 4,5-dihydro-3-methyl-5-oxo-1*H*-pyrazol-1-yl ring, NR¹R² is NH₂, variable R³ is CN (nitrile or cyano), variable L is H, and subscript n is 5. This compound fails to anticipate or render obvious compounds of claims 13 and 15 because a 4,5-dihydro-3-methyl-5-oxo-1*H*-pyrazol-1-yl ring is not equivalent to a 1-methyl-1H-pyrazol-3(2H)-one ring because the double bond is in a different location in the ring. Ibrahim et al. do not teach pharmaceutical compositions comprising compound 3.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to NOBLE JARRELL whose telephone number is (571)272-9077. The examiner can normally be reached on M-F 7:30 A.M - 6:00 P.M. EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. James O. Wilson can be reached on (571) 272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/555,894 Page 5

Art Unit: 1624

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Noble Jarrell/ Examiner, Art Unit 1624 /James O. Wilson/ Supervisory Patent Examiner, Art Unit 1624